State v. Ramey , 2019 Ohio 5087 ( 2019 )

[Cite as State v. Ramey, 2019-Ohio-5087.]
IN THE COURT OF APPEALS OF OHIO
TENTH APPELLATE DISTRICT
State of Ohio, :
No. 19AP-642
Plaintiff-Appellee, : (C.P.C. No. 18CR-587)
v. : No. 19AP-643
(C.P.C. No. 18CR-2623)
William L. Ramey, Jr., :
(REGULAR CALENDAR)
Defendant-Appellant. :
D E C I S I O N
Rendered on December 10, 2019
On brief: Ron O'Brien, Prosecuting Attorney, and Steven L.
Taylor, for appellee.
On brief: Todd W. Barstow, for appellant.
Argued: Todd W. Barstow.
APPEALS from the Franklin County Court of Common Pleas
KLATT, P.J.
{¶ 1} In these consolidated appeals, defendant-appellant, William L. Ramey, Jr.,
appeals from a judgment of the Franklin County Court of Common Pleas ordering that he
be forced to take certain psychotropic medications to restore competency to stand trial. For
the reasons outlined below, we affirm.
{¶ 2} On February 6, 2018, appellant was indicted in Franklin C.P. No. 18CR-587
on two counts of burglary in violation of R.C. 2911.12, both second-degree felonies, and two
counts of theft in violation of R.C. 2913.02, both fifth-degree felonies. On June 1, 2018,
appellant was indicted in Franklin C.P. No. 18CR-2623 on one count of possession of heroin
in violation of R.C. 2925.11, a first-degree felony.
Nos. 19AP-642 and 19AP-643 2
{¶ 3} During the course of the criminal proceedings, the issue of appellant's
competency arose, and, by entry filed on March 20, 2019, the trial court found appellant
incompetent to stand trial. The court ordered appellant to undergo treatment at Twin
Valley Behavioral Healthcare ("Twin Valley") for a period of one year. Upon appellant's
refusal to voluntarily take medication prescribed by Twin Valley medical staff, Twin Valley
petitioned the trial court for authorization for the involuntary administration of
psychotropic medication to appellant. Following a hearing, the trial court issued a
judgment entry on April 22, 2019 ordering appellant to take the medication prescribed by
Twin Valley and authorizing Twin Valley to involuntarily administer the medication if
appellant refused.
{¶ 4} Following appellant's appeal of that order and the parties' subsequent joint
motion for an entry of judgment, this court issued a judgment entry on August 14, 2019 in
which it sustained appellant's sole assignment of error "by agreement of the parties,"
reversed the trial court's judgment, and remanded the matter to the trial court "for an
evidentiary hearing on whether or not medications administered to appellant will be
substantially likely to render the defendant competent to stand trial and, at the same time,
whether or not such medications will be substantially unlikely to have side effects that will
interfere significantly with the defendant's ability to assist counsel in conducting a trial
defense." State v. Ramey, 10th Dist. No. 19AP-287 (Aug. 14, 2019 Jgmt. Entry.)
{¶ 5} In accordance with the remand, the trial court held a hearing on
September 17, 2019. Thereafter, on September 19, 2019, the trial court issued a judgment
ordering appellant to take the prescribed medication and authorizing Twin Valley to
administer the medication upon appellant's continued refusal. Appellant timely appealed
the trial court's judgment.1
{¶ 6} Appellant sets forth a single assignment of error for our review:
The trial court erred to the prejudice of appellant by failing to
make evidence-based findings in ordering appellant to
undergo a regimen of forced medication in an effort to restore
him to compentence [sic] to stand trial.
1 Franklin C.P. No. 18CR-587 is docketed as 19AP-642; Franklin C.P. No. 18CR-2623 is docketed as 19AP-
643. By journal entry filed September 25, 2019, this court sua sponte consolidated the appeals for purposes
of record filing, briefing, oral argument, and determination. By journal entry filed October 15, 2019, a
majority of the panel assigned to hear this appeal granted appellant's motion to stay execution of judgment
pending appeal.
Nos. 19AP-642 and 19AP-643 3
{¶ 7} At the outset, we note that the Supreme Court of Ohio has determined that
"when a trial court orders an incompetent defendant to be forcibly medicated with
psychotropic drugs in an effort to restore the defendant to competency, that order is final
and appealable." State v. Muncie, 91 Ohio St.3d 440, 452 (2001). In the present case,
appellant argues that the trial court erred in permitting the involuntary administration of
medication in order to restore his competency to stand trial on the burglary, theft, and
possession of heroin charges on which he was indicted. Appellant essentially asserts that
the trial court erred in ordering him to undergo the involuntary administration of
medication without complying with the requirements set forth in Sell v. United States, 539
U.S. 166 (2003). We disagree.
{¶ 8} Before examining the principles established by the United States Supreme
Court in Sell, we note the statutory basis governing the involuntary administration of
medication to a criminal defendant set forth in R.C. 2945.38(B)(1)(c):
If the defendant is found incompetent to stand trial, if the
chief clinical officer of the hospital, facility, or agency where
the defendant is placed, or the managing officer of the
institution, the director of the program or facility, or the
person to which the defendant is committed for treatment or
continuing evaluation and treatment under division (B)(1)(b)
of this section determines that medication is necessary to
restore the defendant's competency to stand trial, and if the
defendant lacks the capacity to give informed consent or
refuses medication, the chief clinical officer of the hospital,
facility, or agency where the defendant is placed, or the
managing officer of the institution, the director of the
program or facility, or the person to which the defendant is
committed for treatment or continuing evaluation and
treatment may petition the court for authorization for the
involuntary administration of medication. The court shall
hold a hearing on the petition within five days of the filing of
the petition if the petition was filed in a municipal court or a
county court regarding an incompetent defendant charged
with a misdemeanor or within ten days of the filing of the
petition if the petition was filed in a court of common pleas
regarding an incompetent defendant charged with a felony
offense. Following the hearing, the court may authorize the
involuntary administration of medication or may dismiss the
petition.
Nos. 19AP-642 and 19AP-643 4
{¶ 9} R.C. 2945.38(B)(1)(c) does not set forth specific standards for a trial court to
apply in determining whether to order the involuntary administration of medication to
restore a criminal defendant's competence to stand trial. State v. McClelland, 10th Dist.
No. 06AP-1236, 2007-Ohio-841, ¶ 4; State v. Brewer, 12th Dist. No. CA2008-04-040,
2008-Ohio-6193, ¶ 9. However, in Sell, the United States Supreme Court addressed
whether the "forced administration of antipsychotic drugs to render [a defendant]
competent to stand trial unconstitutionally deprive[s] [a defendant] of his [or her] 'liberty'
to reject medical treatment." Id. at 177. The court determined that "[t]he Constitution
permits the Government involuntarily to administer antipsychotic drugs to a mentally ill
defendant facing serious criminal charges in order to render that defendant competent to
stand trial, but only if the treatment is medically appropriate, is substantially unlikely to
have side effects that may undermine the fairness of the trial, and, taking account of less
intrusive alternatives, is necessary significantly to further important governmental trial-
related interests." Id. at 179. The Court formulated a four-factor test to determine whether
the involuntary administration of medication may be used in order to render a defendant
competent to stand trial. Id. at 180-81.
{¶ 10} The first factor requires the trial court to find that "important governmental
interests are at stake," i.e., prosecuting and punishing an individual who has been accused
of a serious crime. Id. at 180. The second factor requires the court to conclude that
involuntary medication will "significantly further" those concomitant governmental
interests. Before so concluding, the court must find that administration of the drugs is both
"substantially likely to render the defendant competent to stand trial" and "substantially
unlikely to have side effects that will interfere significantly with the defendant's ability to
assist counsel in conducting a trial defense, thereby rendering the trial unfair." Id. at 181.
The third factor requires the court to conclude that involuntary medication is "necessary"
to further the government's interests. In so concluding, the court must find that "any
alternative, less intrusive treatments are unlikely to achieve substantially the same results."
Id. The fourth and final factor requires the court to conclude that administration of the
drugs is "medically appropriate," i.e., in the patient's best medical interest in light of his or
her medical condition. Id. The trial court must make specific findings regarding the factors
and sub-factors enunciated in Sell because "without specific findings, a thorough and
Nos. 19AP-642 and 19AP-643 5
appropriate appellate review of the trial court's decision would be impossible." McClelland
at ¶ 9.
{¶ 11} Here, the trial court made all the specific findings required by Sell; appellant
concedes as much. (Appellant's brief at 5, 6 ("the trial court considered the Sell factors";
"[t]he trial court's decision cites the Sell factors")). However, appellant challenges the
evidence underlying the trial court's finding under the second prong of the Sell test, i.e.,
that "[a]dministration of the drugs is substantially unlikely to have side effects that will
interfere significantly with the defendant's ability to assist counsel in conducting a trial
defense in a way that would render the trial unfair." (Sept. 19, 2019 Entry at 2.)
Appellant's challenge essentially requires us to review the trial court's finding in this regard
to determine whether it is against the manifest weight of the evidence. In so doing, "we
remain mindful that judgments supported by some competent, credible evidence
addressing all the essential elements of the case will not be reversed on appeal as against
the manifest weight of the evidence." In re J.F., 10th Dist. No. 06AP-1225, 2007-Ohio-
2360, ¶ 23, citing In re T.B., 10th Dist. 06AP-769, 2006-Ohio-4789, ¶ 7, citing C.E. Morris
Co. v. Foley Constr. Co., 54 Ohio St.3d 279 (1978).
{¶ 12} At the September 17, 2019 hearing, Gary Davis, M.D., the attending
psychiatrist at Twin Valley who prepared the application to authorize forced psychotropic
medications (Joint Ex. 1),2 testified3 on direct examination that appellant's "working"
psychological diagnosis is "schizoaffective disorder" and that "medications were necessary
to correct that disorder so that he would become competent to stand trial." (Sept. 17, 2019
Tr. at 7.) Dr. Davis averred that the plan to restore appellant's competency involved the
administration of Haldol, one of three antipsychotic medications4 utilized to aid in
"thinking, focus, perception, [and] mood," along with Cogentin to reduce the side effects of
Haldol. Id. When questioned about the side effects of Haldol, Dr. Davis responded that
"the Cogentin would be to prevent things like tremor or muscle contractions." Id. at 8. He
2 The application is signed by both Dr. Davis and Dr. Ann Morrison, Chief Clinical Officer at Twin Valley.
3Both parties subpoenaed Dr. Davis and stipulated that he would testify as an expert witness. (Sept. 17,
2019 Tr. at 5, 6.)
4 The two other antipsychotic medications listed in Joint Ex. 1 are Prolixin and Thorazine.
Nos. 19AP-642 and 19AP-643 6
further acknowledged a risk of "sedation" with use of Haldol, but stated that such risk can
generally be managed with dosage adjustments and medication changes. Id. at 8, 20.
{¶ 13} Dr. Davis further testified that if Haldol or one of the other psychotropic
medications failed to restore appellant to competency, he would consider administering
one of several "atypical antipsychotic" medications,5 which are "less likely to cause some of
the motor side effects of the old antipsychotics." Id. He further averred that those
medications also have side effects, including sedation, tremor and muscle contractions, and
dizziness, which could be managed "with dosage adjustments" such as "adding a medicine
to combat the side effects [or] switching to another medicine." Id. at 9. Dr. Davis opined
that if appellant did not take psychotropic medication, he would "not have any
improvement" and "not be restored to competency." Id. He further testified "within a
reasonable degree of psychiatric certainty, that there's substantial likeliness that
[appellant] would be rendered competent to stand trial if he does take these medications."
Id. When questioned about the "substantial unlikeliness" of the side effects interfering
significantly with appellant's ability to assist his attorney at trial, Dr. Davis responded that
he "would expect the medication side effects not to interfere with [appellant's] ability to
work with his attorney and have a fair trial." Id. at 10. He further opined that there are
no reasonable alternative treatments to the use of these medications and that
administration of the medications was medically appropriate.
{¶ 14} On cross-examination, counsel for appellant questioned Dr. Davis about the
potential side effects of Haldol, including "difficulty with speaking or swallowing,"
[i]nability to move the eyes," "mask-like face," and "Parkinson-ism," which involves
"twisting movements of the body or torso." Id. at 11-12. Dr. Davis readily acknowledged
these potential side effects. However, he described "difficulty with speaking or swallowing"
as "rare," "eye movement" issues as "uncommon" and treatable with Cogentin, "mask-like
face" as possible over "weeks to months," and "Parkinson-ism" as "possible." Id. Dr. Davis
also acknowledged possible side effects of Cogentin, including "confusion about orientation
to time or place," which he asserted "could happen" "[a]t high doses in an older patient."
5The "atypical antipsychotic" medications listed in Joint Ex. 1 are Olanzapine, Risperdal, Risperdal Consta,
Geodon, Clozapine, Seroquel, and Abilify.
Nos. 19AP-642 and 19AP-643 7
Id. at 12. He also acknowledged that he could not predict "precisely what side effects
[appellant] would have" were he prescribed the "Cogentin-Haldol mix." Id. at 13.
{¶ 15} Dr. Davis testified that the initial administration of the Haldol-Cogentin drug
regimen would occur at Twin Valley. Thereafter, if appellant were restored to competence,
he might remain at Twin Valley or be transferred to the Franklin County Jail to await trial.
Dr. Davis averred that in the latter case, "I think they have nursing staff and physicians that
work in the jail" and that it would likely not be a physician from Twin Valley ordering and
authorizing the medications. Id. at 14. In contrast, if appellant remained at Twin Valley
and began exhibiting side effects, the Twin Valley medical staff would adjust the dosages of
Haldol or Cogentin, or both, or, if necessary, switch to one of the "atypical antipsychotic"
medications. Id. at 15-16. Dr. Davis acknowledged that medication adjustments would be
difficult to achieve during trial, but opined that he "wouldn't expect" the sudden occurrence
of side effects at trial. Indeed, he described this scenario as "pretty unlikely." Id. at 20.
{¶ 16} Dr. Davis opined that administration of Haldol typically takes a "[m]atter of
weeks" to have the desired medical effect on a patient; discontinuing use abruptly would
result in a return of psychiatric symptoms within "weeks, months [or] a year." Id. at 18.
He further opined that the desired medical effect of Cogentin would occur "in an hour or
two," with abrupt discontinuance resulting in "undesirable [e]ffects" to manifest in "hours
to a day or two." Id. at 19. He acknowledged that the length of time a patient had been on
antipsychotic medication or Cogentin would impact the possible return of psychiatric
symptoms.
{¶ 17} Counsel for appellant then posed a series of questions concerning the
procedures to be employed if appellant were housed at Twin Valley during the trial
proceedings. Counsel first asked, "during a trial, Twin Valley would monitor [appellant]
for side effects before he left in the morning. Correct?" Dr. Davis responded, "[y]es." Id.
at 20-21. Counsel then asked "[w]ould there be someone [at trial] to monitor side effects
during the day * * * when he's in trial all day long?" Id. at 21. Dr. Davis replied, "[n]o, but
I don't think that's necessary" because "it would be highly unlikely that [appellant] would
suddenly have some new side effects during the day." Id. Upon further questioning, he
averred, "I suppose it's within the realm of possible, but unlikely." Id. Counsel next
inquired, "if Mr. Ramey was getting ready to come to court and he was exhibiting symptoms
Nos. 19AP-642 and 19AP-643 8
of * * * Parkinson-ism * * * would Twin Valley still allow him to come to court if those
symptoms were present?" Dr. Davis responded, "I don't know exactly how that would be
handled. I don't think I've ever encountered that situation. * * * I've never seen [side effects]
develop * * * like you seem to be talking about, you know, right before they go to court. It
tends to come on over a period of weeks or longer." Id. at 21-22. Counsel then asked if the
side effects "comes on over a period of weeks, and * * * really start to manifest themselves"
the day trial commences, "what's the plan at Twin Valley to decide whether or not Mr.
Ramey comes to the courthouse or stays at Twin Valley?" Id. at 22. Dr. Davis responded,
"Yeah, I really don't know whose call that is." Id.
{¶ 18} Counsel then asked several questions concerning the procedures to be
utilized if appellant were housed at the Franklin County Jail during the trial. Counsel first
asked if "it would be up to the jail medical staff to administer the medications." Id. Dr.
Davis replied, "[c]orrect, that's my understanding. Id. at 23. Counsel then inquired, "the
doctor [at the jail] would be the one who would be determining which medications to give
him * * * [a]nd dosage and all that? Id. Dr. Davis responded "yes." Id. Counsel then asked,
"[w]ould they necessarily have to follow the list that you put in your report, or could they *
* * say, "[w]ell, this is what Mr. Ramey needs." Id. Dr. Davis answered that if appellant
were not taking the medication voluntarily, "my understanding is he would need to stick to
what's listed in the report." Id. Dr. Davis admitted that he did not know the medical
specialty of the medical director of the Franklin County Jail. Id. at 23-24.
{¶ 19} On redirect examination, Dr. Davis reiterated his opinion that the side effects
of all the medications discussed during the hearing were "manageable" and that "the
sudden onset of new side effects during a trial is highly unlikely." Id. at 24. He further
testified that many criminal-defendant patients medicated with psychotropic drugs to
restore them to competency prefer to stay at Twin Valley during the course of trial. When
asked if this was so because Twin Valley monitors patients more closely, Dr. Davis stated,
"[w]ell, I can't say * * * the frequency of our monitoring versus the jail." Id. at 25. He then
stated, "I think a big concern a lot of times is that a person would stop taking their medicines
if they went back to jail. That's a concern that we have fairly often." Id.
Nos. 19AP-642 and 19AP-643 9
{¶ 20} On recross-examination, appellant's counsel asked whether Cogentin "will
completely block" the side effects of Haldol or other psychotropic medications. Id. Dr.
Davis responded, "I think it lowers the risk, but it's not an ironclad guarantee." Id. at 26.
{¶ 21} As noted above, in addition to Dr. Davis's testimony, the parties submitted
and stipulated to Joint Ex. 1. That report substantially echoes Dr. Davis's testimony
regarding the potential side effects of psychotropic medications. Under the subsection
entitled "[t]he nature, degree, duration, and probability of side effects and/or significant
risks," it states, "[t]he patient might experience akathisia (restlessness). Common, but
treatable, extra pyramidal side effects include dystonia, dyskinesia, and akathisia. The
patient will be closely monitored in order to minimize the likelihood of tardive dyskinesia.
We will watch for other possible side effects such as sedation, gait disturbance, GI
complaints, tremors, agranulocytosis, drooling, tachycardia, elevated blood sugars and
seizures." (Joint. Ex. 1.)
{¶ 22} Appellant contends that Dr. Davis's testimony does not support the trial
court's finding that the potential side effects associated with the administration of Haldol
will not interfere significantly with appellant's ability to receive a fair trial. In support,
appellant cites Justice Kennedy's concurring opinion in Riggins v. Nevada, 504 U.S. 127(1992), wherein he outlined the unwanted side effects of psychotropic medications as well
as the potentially negative impact such side effects may have on a defendant's Sixth
Amendment right to receive a fair trial. Indeed, Justice Kennedy noted that the side effects
of psychotropic medications "can prejudice the accused in two principal ways: (1) by
altering his demeanor in a manner that will prejudice his reactions and presentation in the
courtroom, and (2) by rendering him unable or unwilling to assist counsel." Id. at 142.
{¶ 23} We take no issue with Justice Kennedy's pronouncements in Riggins.
However, we find that Dr. Davis's testimony addresses and satisfies the concerns raised by
Justice Kennedy. As noted above, Dr. Davis expressly testified that he "would expect the
medication side effects not to interfere with [appellant's] ability to work with his attorney
and have a fair trial." (Sept. 17, 2019 Tr. at 10.) In addition, Dr. Davis addressed the specific
concerns raised by appellant's counsel pertaining to each of the potential side effects of
Haldol, opining that those side effects are "rare" and "uncommon" and are treatable with
Cogentin.
Nos. 19AP-642 and 19AP-643 10
{¶ 24} Appellant's chief argument concerns Dr. Davis's alleged "fail[ure] to describe
how Appellant's symptoms would be managed," i.e., "by whom they would be managed if
he was held at the county jail; or who at [Twin Valley] (or the county jail) would determine
if Appellant would be taken into the courtroom each day." (Appellant's brief at 6.) To be
sure, Dr. Davis admitted uncertainty about the hypothetical scenarios posed by appellant's
counsel regarding symptom management during trial. However, Dr. Davis repeatedly
emphasized that the side effects of Haldol were manageable with dosage adjustments,
medication changes, or both, that the sudden development of debilitating side effects
during the trial would be "highly unlikely," and that he had never encountered such
circumstances.
{¶ 25} As noted by appellee, State of Ohio, appellant's argument is based on
hypothetical scenarios the trial court was not required to accept. At oral argument, counsel
for appellant averred that appellant is currently housed at Twin Valley. At this juncture,
neither this court nor the trial court are able to predict whether appellant will remain at
Twin Valley once he is found competent to stand trial, or whether he will be transported to
the Franklin County jail for the trial proceedings. Moreover, neither this court nor the trial
court are able to predict what side effects, if any, appellant may experience. Indeed, Dr.
Davis, appellant's own treating psychiatrist, testified that he could not predict "precisely
what side effects [appellant] would have" were he prescribed the Haldol/Cogentin mix. (Tr.
at 13.) Accordingly, it would be quite difficult, if not impossible, for Dr. Davis to opine with
any specificity as to hypothetical arguments about where appellant will be housed during
trial or how the development of potentially debilitating side effects during trial would be
managed, particularly given his testimony that such scenario was unlikely to occur.
Appellant's hypothetical arguments are mere speculation and do not negate Dr. Davis's
testimony that the side effects of Haldol can be managed with dosage adjustments,
medication changes, and use of Cogentin and will not interfere with his right to a fair trial.
We further note that should such side effects develop during trial, appellant's trial counsel
may request, or the trial court may sua sponte order, additional proceedings regarding
appellant's competency.
{¶ 26} The present case is similar to Brewer, 12th Dist. No. CA2008-04-040, 2008-
Ohio-6193, wherein the appellate court held that the trial court's finding that "the
Nos. 19AP-642 and 19AP-643 11
administration of medications is substantially unlikely to have side effects that will interfere
significantly with the defendant's ability to assist his counsel in conducting a trial defense"
was supported by the testimony of the defendant's attending forensic psychiatrist who had
been treating the defendant while he was committed to a psychiatric hospital in order to
restore competency. There, the psychiatrist testified that the "doses of each drug
[prescribed] were not likely to result in those severe side effects, [and that] if any
medication presented side effects which negatively affected the defendant's ability to
communicate, think, or generally assist with his defense, the medication would be
immediately adjusted or discontinued to abate these negative effects." Id. at ¶ 25. The
testimony provided by Dr. Davis is substantially similar to that of the psychiatrist in
Brewer. After reviewing Dr. Davis's testimony, as well as Joint Ex. 1, we find no error in
the trial court's conclusion that "[a]dministration of the drugs is substantially unlikely to
have side effects that will interfere significantly with the defendant's ability to assist counsel
in conducting a trial defense in a way that would render the trial unfair." Accordingly,
appellant's assignment of error is overruled.
{¶ 27} Having overruled appellant's sole assignment of error, we hereby affirm the
judgment of the Franklin County Court of Common Pleas.
Judgment affirmed.
SADLER and LUPER SCHUSTER, JJ., concur.